Effects of Atorvastatin on Bone in Postmenopausal Women with Dyslipidemia: A Double-Blind, Placebo-Controlled, Dose-Ranging Trial | Zendy

Henry G. Bone | Zendy; Douglas P. Kiel | Zendy; Robert S. Lindsay | Zendy; E. Michael Lewiecki | Zendy; Michael A. Bolognese | Zendy; Elizabeth Leary | Zendy; Wing Lowe | Zendy; Michael R. McClung | Zendy

Open Access

Effects of Atorvastatin on Bone in Postmenopausal Women with Dyslipidemia: A Double-Blind, Placebo-Controlled, Dose-Ranging Trial

Author(s) -

Henry G. Bone,

Douglas P. Kiel,

Robert S. Lindsay,

E. Michael Lewiecki,

Michael A. Bolognese,

Elizabeth Leary,

Wing Lowe,

Michael R. McClung

Publication year - 2007

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2006-1909

Subject(s) - atorvastatin , bone mineral , placebo , medicine , bone density , endocrinology , osteoporosis , context (archaeology) , bone remodeling , dyslipidemia , urology , biology , obesity , pathology , alternative medicine , paleontology

In preclinical models, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase have been shown to positively affect bone remodeling balance. Observational studies and secondary analyses from lipid-lowering trials have yielded inconsistent results regarding the effect of these agents on bone mineral density and fracture risk.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research